Autifony's clinical-stage programmes include AUT00206, a Kv3 modulator for Fragile X syndrome with FDA Orphan Drug Designation, and AUT00201 for rare myoclonic epilepsy syndromes. The company also has preclinical programmes targeting Kv3 channels for schizophrenia and hearing loss, and early-stage programmes focused on other ion channel targets for neurodegenerative and hyperexcitability disorders.
The management team comprises experts in ion channel drug discovery with experience spanning target validation through to proof-of-concept in patients. The company has focused science teams in medicinal chemistry, molecular and cell biology, and electrophysiology, plus a clinical team experienced in designing and leading clinical trials. The team has particular expertise in using non-invasive CNS biomarkers and designing clinical trials in hearing disorders.
This is the employer describing itself, in its own words. We do not rate or review employers, and nothing here is our opinion of one.